BEGIN:VCALENDAR VERSION:2.0 PRODID:icalendar-ruby CALSCALE:GREGORIAN BEGIN:VEVENT DTSTAMP:20240328T144823Z UID:ac0af0f1-ad68-4a6a-b57e-8d43f03e3a83 DTSTART:20210923T080000 DTEND:20210924T080000 CLASS:PRIVATE DESCRIPTION:
About
\n\n
\nR
are Diseases 2020
\n
\nDetails of Rare Diseases 2020 in
USA
\nConference Name Place Date
\nRare Diseases 2020 Toronto\,
Canada September 23-24\, 2020
\n
\nOn behalf of the organizing
committee\, we are pleased to announce that the 10th Annual Congress on Ra
re Diseases and Orphan Drugs (Rare Diseases 2020) will be held from Septem
ber 23-24\, 2020 in Toronto\, Canada. Rare Diseases 2020 provides a premie
r interdisciplinary platform for researchers to present the latest researc
h findings and describe emerging technologies\, and directions in rare dis
eases and orphan drugs issues. The conference seeks to contribute to prese
nting novel research results in all aspects of Rare Diseases and Orphan Dr
ugs.
\n
\nThe conference aims to bring together leading academic
scientists\, researchers and research scholars to exchange and share thei
r experiences and research results about all aspects of rare diseases and
orphan drugs. It also provides the premier interdisciplinary forum for sci
entists\, professors\, specialists\, researchers\, students and practition
ers to present their latest research results\, ideas\, developments\, and
applications in all areas of rare diseases and orphan drugs. The conferenc
e will bring together leading academic scientists\, researchers\, Industri
al delegates Healthcare Professionals and scholars in the domain of intere
st from around the world.
\n
\nThe conference'\;s goal will t
o provide a scientific forum for all international prestige scholars aroun
d the world and enable the interactive exchange of state-of-the-art knowle
dge. The conference will focus on evidence-based benefits proven in clinic
al trials and scientific experiments.
Why to attend?
\n
\nJoin the Rare Diseases and Orphan Drugs Congress to k
eep up to date with the industry and to learn from our expert speaker pane
l\, bringing you important new case studies and reports on this year'\;
s relevant topics.
\n
\nLearn more about global trends in rare d
iseases and its advances in the therapeutic and diagnostic market.
\n
Discussing strategic win-win collaborations to help accelerate rare diseas
e clinical drug development\, and improve relationships between drug devel
opers and patients to consider both parties interests
\nHear more abo
ut how patient engagement by integrating the patient perspective into the
drug development process through patient advocacy\, patient-centric resear
ch\, and patient groups
\nLearn about how the regulatory landscape fo
r drug approvals is different between countries\, and why it is important
to keep informed about the regulations and guidelines of each region
\nGain knowledge of different rare diseases and their unique challenges\,
as well as how treatment methods can be transferred to other rare diseases
\nIntroducing cell and gene therapies to rare disease treatment - le
arn how gene therapy methods can improve the treatment of rare diseases an
d why it is becoming more commercially successful
\n
\nM
arket Analysis
\n
\nImportance and Scope
\n
\nA rare/orphan disease is outlined as a condition that af
fects fewer than 200\,000 people. This definition was created by Congress
within the Orphan Drug Act of 1983. There may be as many as 7\,000 rare di
seases and 70% of them have no form of treatment. Regulatory edges like lo
nger market exclusivity\, breakthrough designations\, reduced fees and tax
incentives are all encouraging investment. However\, the marketing proces
s and lifecycle for a rare disease drug are very different to a mass marke
t product and require particular skills and knowledge.
\n
\nRare
Diseases 2020 will be the best platform for all the doctors\, researchers
\, renowned Scientists\, research scholars\, students who are working in t
his field across the globe under a single roof to exchange their knowledge
related to Rare Diseases and Orphan Drugs. This international event is an
effort to find an alternative for invasive imaging technique against rare
diseases like Zellweger syndrome\, Muscular Dystrophy\, Alkaptonuria\, An
gelman syndrome\, Prader-Willi syndrome\, Tay Sachs disease\, Fragile X sy
ndrome\, Gaucher disease as well as many others.
\n
\nCo
nference Highlights
\n
\n·\; Different types of R
are Diseases
\n
\n·\; Clinical Research and Public Awarene
ss
\n
\n·\; Mystery Diagnosis of Rare Diseases
\n
\n·\; Challenges in Rare Diseases Treatment
\n
\n·
\; Rare Infectious Diseases and Immune Deficiencies
\n
\n·
\; Rare Diseases in Cancer
\n
\n·\; Rare Diseases in Aging
\n
\n·\; Orphan Drugs- development trends and strategies<
br />\n
\n·\; Clinical Research on Orphan Drugs
\n
\n
·\; Orphan Drugs and Ethical Issues
\n
\n·\; Future
Hereditary of Rare Diseases and Orphan Drugs
\n
\n·\; Pati
ent organizations and their role in drug development or clinical research<
br />\nWhy attend?
\n
\nIn today'\;s economic climate your bu
siness selections are as crucial as ever. 6th Annual Congress on Rare Dise
ases and Orphan Drugs (Rare Diseases 2020) allow you to maximise your time
and marketing dollars whereas receiving immediate feedback on your new me
rchandises and services. Rare Diseases 2020 is organizing an outstanding S
cientific Exhibition/Program and expects the world'\;s leading speciali
sts involved Rare Diseases and Orphan Drugs. Your company will benefit wit
h outstanding exposure to the leaders in Rare Diseases and Orphan Drugs. R
are Diseases 2020 is a stimulating opportunity to showcase the new technol
ogy\, the new products of your company\, and/or the service your industry
may offer to a wide-ranging international audience.
Targ
et Audience
\n
\nJoin the Rare Diseases and Orphan Drug
s congress to keep up to date with the industry and to learn from our expe
rt speaker panel\, bringing you important new case studies and reports on
this year&rsquo\;s relevant topics.
\n
\n·\; Directors\, B
oard Members\, Presidents\, Vice Presidents\, Deans and Head of the Depart
ments
\n
\n·\; Researchers\, Scientists\, Faculties\, Stud
ents
\n
\n·\; Rare Diseases Associations and Societies
\n
\n·\; Medical Colleges
\n
\n·\; Industrial
delegates from Academia and Research
\n
\n·\; Industrial
professionals from biomedical companies and healthcare sectors
\n
\n·\; Medical Devices Manufacturing Companies
\n
\n&midd
ot\; Drug Manufacturing Companies and Industries
\n
\n·\;
Laboratory Technicians and Diagnostic Companies
\n
\n·\; B
usiness Entrepreneurs and Industrialists
\n
\nA Unique Opportuni
ty for Advertisers\, exhibitors\, and Sponsors at 10th Annual Congress o R
are Diseases and Orphan Drugs (Rare Diseases 2020): http://rarediseases.co
nferenceseries.com/sponsors.php
\n
\nStatistics of Researchers\,
Academicians\, and Industrial
\n
\nMajor Associations W
orldwide
\n
\n·\; National Organization for Rare
Diseases
\n
\n·\; Canadian Organization for Rare Diseases<
br />\n
\n·\; Organization for Rare Diseases India
\n
\n·\; The Boler-Parseghian Center for Rare &\; Neglected Disease
s
\n
\n·\; Cystic Fibrosis Foundation
\n
\n&midd
ot\; European Union Committee of Experts on Rare Diseases
\n
\n&
middot\; Multiple Myeloma Research Foundation
\n
\n·\; U.S
. Food and Drug Administration
\n
\n·\; Birmingham childre
n&rsquo\;s Hospital
\n
\n·\; EURORDIS
\n
\n&midd
ot\; EveryLife Foundation for Rare Diseases
\n
\n·\; Globa
l Genes
\n
\n·\; Rare Diseases South Africa
\n
\
n·\; Short Bowel Syndrome Foundation
\n
\n·\; Rare D
isorders Society Singapore
\n
\n·\; Genetic and Rare Disea
ses Information Center (GARD)
\n
\n·\; Students4RareDiseas
es
\n
\n·\; Malaysian Rare Disorders Society
\n
\n·\; New Zealand Organisation for Rare Disorders (NZORD)
\n
\n·\; Rare Disease United Foundation
\n
\n·\; Rar
e Diseases Denmark
\n
\n·\; Genetic Alliance UK
\n
\n·\; Rare Voices Australia
\n
\n·\; BioPontis Al
liance for Rare Diseases
\n
\n·\; Rare Diseases Malta
\n
\n·\; The International Rare Diseases Research Consortium (
IRDiRC)
\n
\n·\; Genetic Diseases Association - UAE
\
n
\n·\; National Tay-Sachs and Allied Diseases (NTSAD)
\n<
br />\nTop Universities Worldwide
\n
\n·\; Harvard Univers
ity
\n
\n·\; University of Oxford
\n
\n·\;
University of Cambridge
\n
\n·\; Rare Genomics Institute<
br />\n
\n·\; GMEC\, The Global Medical Excellence Cluster
\n
\n·\; University of Zurich
\n
\n·\; Stanfor
d University
\n
\n·\; Cambridge University
\n
\n
·\; Yale University
\n
\n·\; Emory University
\
n
\n·\; Karolinska University
\n
\n·\; John Hop
kins University
\n
\n·\; Newcastle University \;
\n
\n·\; University of Valencia
\n
\n·\; Osaka
University
\n
\n·\; McMaster University
\n
\nHos
pitals Associated with Rare Diseases Research Worldwide
\n
\n&mi
ddot\; The Manton Center for Orphan Disease Research (Boston\, USA)
\
n
\n·\; US hospital for rare disease research (USA)
\n
\n·\; NORD- National Organization for Rare Disorders (USA)
\n
\n·\; Chicago Rare Disease Foundation (Chicago\, USA)
\n<
br />\n·\; National Institute of Health (NIH) funds research consort
ia to study more than 200 rare diseases (USA)
\n
\n·\; Chi
ldren&rsquo\;s Hospital of Pittsburgh (Center for Rare Disease Therapy) (U
SA)
\n
\n·\; Birmingham children&rsquo\;s Hospital (NHS Fo
undation Trust) (UK)
\n
\n·\; The Children&rsquo\;s Hospit
al of Philadelphia (USA)
\n
\nIndustries Associated with Rare Di
seases Research Worldwide
\n
\n·\; AbbVie
\n
\n&
middot\; Actelion
\n
\n·\; AFM-Telethon
\n
\n&mi
ddot\; Alexion
\n
\n·\; Amgen
\n
\n·\; Ami
cus Therapeutics
\n
\n·\; AstraZeneca
\n
\n&midd
ot\; Baxter
\n
\n·\; Bayer
\n
\n·\; Biogen
\n
\n·\; BioMarin
\n
\n·\; Bioxcel
\
n
\n·\; Bristol-Myers Squibb
\n
\n·\; Celgene\n
\n·\; cydan
\n
\n·\; Eli Lilly
\n\n·\; Genentech
\n
\n·\; Gilead Sciences
\n
\n·\; GlaxoSmithKline
\n
\n·\; Johnson &\;
Johnson
\n
\n·\; Leadiant Biosciences
\n
\n&midd
ot\; Lumos Pharma
\n
\n·\; Medivir
\n
\n·\
; Merck
\n
\n·\; Novartis
\n
\n·\; Novo No
rdisk
\n
\n·\; OrPha Swiss
\n
\n·\; Orphan
Europe
\n
\n·\; orphan reach
\n
\n·\; Pfi
zer
\n
\n·\; Pharmacyclics
\n
\n·\; Pharma
Mar
\n
\n·\; PhRMA
\n
\n·\; ProMetic Life
Sciences
\n
\n·\; Recordati S.p.A.
\n
\n·\
; Roche
\n
\n·\; Sanofi Genzyme
\n
\n·\; S
arepta Therapeutics
\n
\n·\; Shire
\n
\n·\
; Spectrum Pharmaceuticals
\n
\n·\; Swedish Orphan Biovitr
um
\n
\n·\; Takeda
\n
\n·\; Teva
\n\n·\; Ultragenyx
\n
\n·\; Vertex Pharmaceuticals
\n
\n·\; QuintilesIMS
\n
\nGlance at Market ana
lysis report
\n
\nSummary GBI Research\, the leading business in
telligence provider\, has released its latest research &ldquo\;Orphan Dise
ase Therapeutics Market to 2020 &ndash\; Improved Understanding of Rare Di
seases&rsquo\; Heterogeneity and Novel New Clinical Trial Designs to Foste
r Innovation&rdquo\;\, which provides insights into the orphan disease the
rapeutics market until 2020. It includes the geographical distribution of
Fabry\, Pompe\, Mucopolysaccharidosis VI\, Idiopathic Thrombocytopenic Pur
pura\, Huntington&rsquo\;s disease and Ovarian cancer markets across the U
S\, the top five countries of Europe and in Japan. The report provides com
petitive benchmarking for the leading companies and also analyzes the merg
ers\, acquisitions and licensing agreements that shape the global markets.
GBI Research&rsquo\;s analysis shows that the overall global orphan disea
se therapeutics market is expected to grow at a significant compound annua
l growth rate (CAGR) of 13.1% from $2.3 billion 2010 to $6 billion in 2020
in the US\, the top five countries of Europe and Japan. Increasing awaren
ess of the disease and drugs among patients and physicians\, patent protec
tion and exclusivity of Nplate and Promacta for ITP market\, anticipated l
aunch of new molecules such as ACR-16\, AMR-101 and HD-02 for the treatmen
t of HD and the approval of Avastin for the treatment of advanced ovarian
cancer in Europe will drive the global orphan disease therapeutics market
in the forecast period.
\n
\nAnnualized market data for the orph
an diseases therapeutics market from 2004 to 2010\, forecast forward to 20
20.- Analysis of the leading therapeutic segments. These include Fabry Dis
ease\, Pompe Disease and Mucopolysaccharidosis VI\, Idiopathic Thrombocyto
penic Purpura\, Huntington&rsquo\;s disease and Ovarian Cancer.- Analysis
of the orphan diseases therapeutics market in the leading geographies of t
he world\, which include the US\, the UK\, Germany\, France\, Italy\, Spai
n\, and Japan &ndash\; Market characterization of the orphan diseases ther
apeutics market including market size\, annual cost of therapy\, and treat
ment usage patterns &ndash\; Key drivers and barriers that have a signific
ant impact on the market &ndash\; Coverage of pipeline molecules in variou
s phases of drug development &ndash\; Competitive benchmarking of leading
companies. The key companies studied in this report are Genzyme Corporatio
n\, Shire Plc\, and BioMarin - Key M&\;A activities\, licensing agreeme
nts that have taken place between 2010 and 2011 in the global orphan disea
ses therapeutics market.
\n
\nThe 2013 Orphan Drug Report from E
valuate\, which launched today at the 2013 BIO international Convention\,
sheds light on the market dynamics of orphan drugs &mdash\; pharmaceutical
products aimed at rare diseases or disorders &mdash\; projecting that sal
es will experience a compound annual growth rate of 7.4 percent between 20
12 and 2020\, nearly double that of the prescription drug market\, excludi
ng generics. The report based on EvaluatePharma®\; data found that the
worldwide orphan drug market is set to reach $127 billion by 2020\, double
that of the overall prescription drug market.
\n
\nMark
et Growth of Rare Diseases Research
\n
\nGBI Research&r
squo\;s analysis shows that the overall global orphan disease therapeutics
market is expected to grow at a significant compound annual growth rate (
CAGR) of 13.1% from $2.3 billion 2010 to $6 billion in 2020 in the US\, th
e top five countries of Europe and Japan.
\n
\nThe 2013 Orphan D
rug Report from Evaluate\, which launched today at the 2013 BIO internatio
nal Convention\, sheds light on the market dynamics of orphan drugs &mdash
\; pharmaceutical products aimed at rare diseases or disorders &mdash\; pr
ojecting that sales will experience a compound annual growth rate of 7.4 p
ercent between 2012 and 2020\, nearly double that of the prescription drug
market\, excluding generics. The report based on Evaluate Pharma data fou
nd that the worldwide orphan drug market is set to reach $127 billion by 2
020\, doubling that of the overall prescription drug market
\n
\
nThe global orphan drugs market reached $84.9 billion in 2009 growing from
$58.7 billion in 2006 from $54.5 billion in 2005.The market is expected t
o grow at a compound annual growth rate (CAGR) of nearly 6% to reach $112.
1 billion by 2020.The U.S. accounted for 51% of the market in 2009 and is
expected to grow at a CAGR of 8.9% to reach $65.9 billion by 2020.By 2020\
, orphan drugs will own 19% of the total share of prescription drug sale e
xcluding generics\, reaching a whopping $176 billion in annual sales\, acc
ording to Andreas Hadjivasiliou\, an analyst with Evaluatepharma.
\n<
br />\nFund Allotment to Rare Diseases Research
\n\nSince 1989\, NORD&rsquo\;s research grants have resulted in at least
two FDA-approved products and the publication of numerous significant jou
rnal articles. Our more than 100 disease-specific research funds are suppo
rted primarily by patients and patient organizations. Industry support is
welcome and would demonstrate a commitment to the study of diseases for wh
ich there are few if any- other sources of funding.
\n
\nNORD
9\;s Research Program provides seed money grants to academic scientists fo
r clinical studies related to the development of diagnostics or treatments
of rare diseases. Requests for proposals are posted once a year in the la
te winter or early spring. NORD'\;s Research Program also includes the
NORD/Roscoe Brady Lysosomal Storage Diseases Fellowships.
\n
\nP
hysician-scientists at 22 consortia will collaborate with representatives
of 98 patient advocacy groups to advance clinical research and investigate
new treatments for patients with rare diseases. The collaborations are ma
de possible through awards by the National Institutes of Health &mdash\; t
otaling about $29 million in the fiscal year 2020 funding &mdash\; to expa
nd the Rare Diseases Clinical Research Network (RDCRN)\, which is led by N
IH&rsquo\;s National Center for Advancing Translational Sciences (NCATS).<
/p>\n\n
Sessions/Tracks Please c
ontact the event manager Marilyn (marilyn.b.turner(at)nyeventslist.com ) b
elow for: VIO181218CRE
\n
\nThe scientific p
rogram will focus on current advances in the clinical research\, clinical
trials\, drug discovery\, drug development\, drug treatment and orphan dru
g clinical trials with a particular focus on their role in maintaining the
academic level in rare diseases and orphan drugs. In addition\, mentored
sessions for poster presenters will provide guidance from world leaders fo
r our experts of the future.
\n
\nDifferent types of Rar
e Diseases
\n
\nA rare disease is defined as a conditio
n that affects less than 200\,000 people. This explanation was formed by C
ongress in the Orphan Drug Act of 1983. There may be as many as 7\,000 rar
e diseases. Only a few categories of rare diseases are tracked when a pers
on is diagnosed. These include certain infectious diseases\, birth defects
\, and cancers. It also comprises the diseases on state newborn screening
tests. Because most rare diseases are not trailed\, it is hard to determin
e the exact number of rare diseases. Most rare diseases are genetic\, and
thus are present throughout the person'\;s intact life\, even if sympto
ms do not immediately appear.
\n
\nClinical Research and
Public Awareness
\n
\nClinical research is a branch of
healthcare science. The first step in confronting this challenge is regul
arly getting the community to think about participating in clinical resear
ch. People need to consider how they can help advance the prevention\, dia
gnosis\, and treatment of disease. It is never too early to consider contr
ibution whether or not someone finally chooses to join a study.
\n
\nMystery Diagnosis of Rare Diseases
\n
\nDi
agnostic error in medicine is common. For example\, a study from an intens
ive care unit demonstrated nearly 20% discordance between the clinically-d
efined cause of death and findings at post-mortem examination. Not surpris
ingly\; therefore\, the diagnosis of rare diseases is often delayed. Rare
diseases affect likely 2-4% of the population. These diseases often have a
genetic basis\, either as uncommon recessive conditions or as the result
of &ldquo\;de novo&rdquo\; genetic mutations not present in either parent.
They can take varied and often debilitating form.
\n
\n
Challenges in Rare Diseases Treatment
\n
\nThere are ar
ound 7\,000 rare diseases\, which from a regulatory outlook are defined as
those diseases where there are less than 200\,000 patients in the US or t
hat affect no more than five in 10\,000 of the general population in the E
U. Orphan drugs are medicinal products envisioned for diagnosis\, preventi
on\, and treatment of life-threatening rare diseases. They are "\;orph
ans"\; because the pharmaceutical industry has little interest under n
ormal market conditions in developing and marketing drugs intended for onl
y a small number of patients suffering from very rare conditions.
\n<
br />\nRare Infectious Diseases and Immune Deficiencies\n
\nGlobally\, about one-third of human deaths are attributable
to infections. In addition\, the so-called non-infectious causes of death
often have a mysterious infectious etiology. Many rare diseases or orphan
diseases caused by infectious agents rather than genetic or environmental
factors.
\n
\nRare Diseases in Cancer
\n\nRare cancers caused by simple genetic mutations and common cancers t
end to be caused by a complex set of genetic and epigenetic aberrations th
at continually grow in number as the tumor develops. A cancer is considere
d to be rare if- 1. It starts in an uncommon place in the body\, 2. The ca
ncer is an unusual type and may need special treatment\, 3. It is not one
of the common types of cancer.
\n
\nRare Diseases in Agi
ng
\n
\nAging is a collection of degenerative changes t
hat occur in organisms that lack the ability to perpetually regenerate. Ag
e is a major risk factor for most common neurodegenerative diseases. Demen
tia becomes more common with age. The spectrum includes mild cognitive imp
airment\, Alzheimer'\;s disease\, cerebrovascular disease\, Parkinson
39\;s disease and Lou Gehrig'\;s disease. Rare diseases provide much in
sight into the cellular processes that hasten the aging process.
\n\nOrphan Drugs- development trends and strategies
\n
\nThe development of pharma industries has slowed in recent year
s because of many reasons such as patent expiries\, generic competition\,
drying pipelines\, and increasingly stringent regulatory guidelines. Many
blockbuster drugs will lose their exclusivity in next 5 years. Therefore\,
the current economic situation plus the huge generic competition shifted
the focus of pharmaceutical companies from the essential medicines to the
new business model &mdash\; niche busters\, also called orphan drugs.
\n
\nClinical Research on Orphan Drugs
\n
\nA clinical trial is a medical study conducted to test the effects of a
new or already existing drug\, of a biological treatment or of a medical d
evice that might treat or curb a disease already identified. The main goal
of a clinical trial is to compare two or several groups of subjects\, by
using two or several treatments in order to determine the efficacy of a dr
ug or of a biological treatment. Clinical trials are carefully and ethical
ly conducted in order to protect patients against unwanted adverse reactio
ns and to allow collection and accurate analysis of the information concer
ning the disease.
\n
\nOrphan Drugs and Ethical Issues
strong>
\n
\nThis track outlines the moral dilemma of funding or
phan drug research and development. To date\, ethical aspects of priority
setting for research funding have not been an issue of discussion in the b
ioethics debate. Conflicting moral obligations of beneficence and distribu
tive justice appear to demand very different levels of funding for orphan
drug research. The two types of orphan disease\, rare diseases\, and tropi
cal diseases\, however\, present very different ethical challenges to ques
tions about the allocation of research funds. The dilemma is analyzed cons
idering utilitarian and rights-based theories of justice and moral obligat
ions of non-abandonment and a professional obligation to advance medical s
cience. The limitations of standard economic evaluation tools and other pr
iority setting tools used to inform health policy decision makers on resea
rch funding decisions are outlined.
\n
\nFuture Heredita
ry of Rare Diseases and Orphan Drugs
\n
\nWork over the
past 25 years has resulted in the identification of genes responsible for
~50% of the estimated 7\,000 rare monogenic diseases and it is predicted
that most of the remaining disease-causing genes will be identified by the
year 2020 and probably sooner. This marked acceleration is the result of
dramatic improvements in DNA-sequencing technologies and the associated an
alyses. We examine the rapid maturation of rare-disease genetic analysis a
nd successful strategies for gene identification. We highlight the impact
of discovering rare-disease-causing genes\, from clinical diagnostics to i
nsights gained into biological mechanisms and common diseases. Last\, we e
xplore the increasing therapeutic opportunities and challenges that the re
sulting expansion of the '\;Atlas'\; of human genetic pathology will
bring.
\n
\nPatient organizations and their role in dru
g development or clinical research
\n
\nRare disease dr
ug development could benefit substantially from increased patient engageme
nt and input to enhance understanding of the key aspects of disease impact
\, ways to measure these impacts and patients'\; perspectives on the be
nefit-risk profile of potential therapies.
\n
\nEntrepre
neurs Investment Meet
\n
\nA platform aimed to connect
Entrepreneurs\, Proposers and the Investors worldwide. It'\;s intended
to create and facilitate the most optimized and viable meeting place for e
ngaging people in global business discussions\, evaluation and execution o
f promising business ideas. An investor could be able to find out the high
est potential investment opportunities globally\, which provide a good ret
urn on investment. For entrepreneurs\, this would be an ideal place to fin
d out suitable investors and partners to start and/or expand their busines
s. Thus it is a perfect place to connect Entrepreneurs\, Business Owners\,
Early Stage Companies and Established Corporates with National or Interna
tional Investors\, Corporate Investors\, and Potential Business Partners.<
/p>\n\n\n\n
\n- Multiple participant discounts
\n- Price quotation
s or visa invitation letters
\n- Payment by alternate channels (PayPa
l\, check\, Western Union\, wire transfers etc)
\n- Event sponsorship
\n
\nNO REFUNDS ALLOWED ON REGISTRATIONS
\nPrices may go u
p any time. Service fees included in pricing.
\n---------------------
--------------------------------------------
\nThis event is brought
to you by:
\nConference Series - NewYorkEventsList
\nhttp://www.
NyEventsList.com
\nhttp://www.BostonEventsList.com
\nhttp://www.
SFBayEventsList.com
\n-----------------------------------------------
------------------
\n
\nReference:
\
n
\nhttps://www.eventbrite.com/e/10th-annual-congress-on-rare-disease
s-and-orphan-drugs-cse-tickets-53861818148